Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001607062-24-000033
Filing Date
2024-01-19
Accepted
2024-01-19 13:29:02
Documents
52
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q rgbp123123form10q.htm   iXBRL 10-Q 848809
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 9486
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 9486
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 4226
5 EXHIBIT 32.2 ex32_2.htm EX-32.2 4103
  Complete submission text file 0001607062-24-000033.txt   3705119

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rgbp-20231231.xsd EX-101.SCH 38530
7 XBRL CALCULATION FILE rgbp-20231231_cal.xml EX-101.CAL 43170
8 XBRL DEFINITION FILE rgbp-20231231_def.xml EX-101.DEF 138390
9 XBRL LABEL FILE rgbp-20231231_lab.xml EX-101.LAB 219595
10 XBRL PRESENTATION FILE rgbp-20231231_pre.xml EX-101.PRE 196085
46 EXTRACTED XBRL INSTANCE DOCUMENT rgbp123123form10q_htm.xml XML 415030
Mailing Address 4700 SPRING ST #304 LA MESA CA 91942
Business Address 4700 SPRING ST #304 LA MESA CA 91942 619-722-5505
Regen BioPharma Inc (Filer) CIK: 0001589150 (see all company filings)

EIN.: 455192997 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191725 | Film No.: 24544906
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)